Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis

Russell R. Kempker, M. Tobias Heinrichs, Ketino Nikolaishvili, Irina Sabulua, Nino Bablishvili, Shota Gogishvili, Zaza Avaliani, Nestani Tukvadze, Brent Little, Adam Bernheim, Timothy D. Read, Jeannette Guarner, Hartmut Derendorf, Charles A. Peloquin, Henry M. Blumberg, Sergo Vashakidze
Russell R. Kempker
aDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Tobias Heinrichs
bUniversity of Florida, College of Pharmacy, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ketino Nikolaishvili
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Sabulua
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nino Bablishvili
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shota Gogishvili
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaza Avaliani
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nestani Tukvadze
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent Little
dDepartment of Radiology, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Bernheim
dDepartment of Radiology, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy D. Read
aDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeannette Guarner
eDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hartmut Derendorf
bUniversity of Florida, College of Pharmacy, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A. Peloquin
bUniversity of Florida, College of Pharmacy, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry M. Blumberg
aDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
fDepartments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergo Vashakidze
cNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00226-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Serum concentrations of pyrazinamide versus time after dosing in 10 adults with drug-resistant pulmonary tuberculosis.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    (A) Correlation between peak serum pyrazinamide concentration and dosages; (B) correlation between serum free pyrazinamide concentration and lung tissue pyrazinamide concentration. *, Pearson correlation coefficient.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Representative transverse CT views from the seven patients with films available for review. Three main lesions types were identified, including cavitary lesions (a), mass lesions (b), and a consolidation from one patient (c).

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Representative photomicrographs of hematoxylin and eosin-stained specimens for each of the nine patients with tissue pyrazinamide concentrations (listed) available. (a) Cases were classified as severe necrosis when, in addition to what is presented in the photomicrograph, confluent necrosis was present in multiple fields in multiple blocks (two or three blocks). (b) Cases were classified as moderate necrosis when necrosis was confluent with one field. (c) Cases were classified as having rare necrosis when necrosis was scattered within a field. Magnifications, ×4.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Study population characteristics for 10 patients with drug-resistant pulmonary TB

    ParameterValue (n = 10)
    Demographic characteristics
        No. (%) of male patients8 (80)
        Median (range) age (yr)30.2 (15–54)
        No. (%) of patients with the following characteristics:
            Georgian ethnicitya7 (70)
            Diabetes mellitusb1 (10)
            Hepatitis C antibody positive1 (10)
            Hepatitis B surface antigen positive1 (10)
            Alcohol user0
            Tobacco user3 (30)
            Retreatment TB case3 (30)
        Median (range) wt (kg)53.0 (48–71)
        Median (range) body mass index (kg/m2)19.5 (15–22)
    Laboratory values
        Median (range) creatinine clearancec (ml/min)91.1 (52–155)
        Median (range) albumin level (g/dl)4.2 (3.5–4.9)
        Median (range) hemoglobin level (g/dl)13.7 (12.4–15.5)
        Median (range) alanine aminotransferase level (U/liter)18 (10–133)
    Tuberculosis characteristics and treatment
        No. (%) of patient isolates with the following drug susceptibility pattern:
            Isoniazid monoresistant1 (10)
            Isoniazid and ofloxacin resistant1 (10)
            MDR6 (60)
            XDR2 (20)
        No. (%) of patients receiving pyrazinamide at a daily dose ofd:10 (83)
            1,200 mg2 (20)
            1,600 mg8 (80)
        Median (range) pyrazinamide dose (mg/kg)24.7 (22.5–33.3)
        Median (range) no. of days prior to surgery that the patient had received pyrazinamide363 (120–504)
        No. (%) of patients with the following indication for surgical resection:
            Treatment failure and localized lesion1 (10)
            High risk of relapse and localized lesion9 (90)
        No. (%) of patients with the following type of surgery:
            Lobectomy5 (50)
            Segmentectomy5 (50)
    • ↵a One patient was Armenian, one was Azeri, and two were of other ethnicities.

    • ↵b The patient was receiving insulin.

    • ↵c Determined using the Cockcroft-Gault equation.

    • ↵d At the time of surgical resection.

  • TABLE 2

    Noncompartmental analysis of serum pyrazinamide concentrations

    ParameteraMedian (range) valueb
    k el (h−1)0.059 (0.039–0.13)
    t 1/2 (h)11.7 (5.3–17.6)
    T max (h)2.0 (1.7–4)
    C max (μg/ml)37.8 (27.1–54.7)
    AUClast (μg · h/ml)246.7 (69.6–353.1)
    AUC0–∞ (μg · h/ml)827.6 (208.5–1,139.7)
    CL/F (liters/h)1.9 (1.4–7.7)
    V/F (liters)36.4 (28.6–58.5)
    • ↵a k el, elimination rate constant; t1/2, half-life; Tmax, time to Cmax; Cmax, maximal serum concentration; AUClast, area under the serum concentration-versus-time curve at the time of the last concentration determination; AUC0–∞, area under the serum concentration-versus-time curve from time zero to infinity; CL, clearance; V, volume of distribution; F, bioavailability (which was assumed to be 1 for purposes of analysis).

    • ↵b Data are for 10 patients receiving pyrazinamide.

  • TABLE 3

    Comparison of free serum and lung tissue pyrazinamide concentrations among patients with drug-resistant pulmonary TB

    SubjectDose of pyrazinamide (mg/kg)Serum concn at time of resectiona (μg/ml)Tissue concn (μg/ml)Tissue concn/serum concn ratio
    133.3341.04NAbNA
    22428.0325.060.89
    32425.67c13.950.54
    430.7728.9119.780.68
    525.4025.4419.290.76
    63244.7140.170.90
    722.5334.1321.980.64
    829.6327.7225.760.93
    922.8626.9520.960.78
    1022.8623.0017.750.77
    Median (range) 27.8720.960.77 (0.54–0.93)
    • ↵a Free serum concentration = measured pyrazinamide concentration × 0.85 (29).

    • ↵b NA, no lung tissue concentration was available for subject 1 due to a low dialysate volume.

    • ↵c For this patient, the serum concentration at the time of surgical resection was estimated with a one-compartment pharmacokinetic model.

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Tables S1 to S3

      PDF, 159K

PreviousNext
Back to top
Download PDF
Citation Tools
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis
Russell R. Kempker, M. Tobias Heinrichs, Ketino Nikolaishvili, Irina Sabulua, Nino Bablishvili, Shota Gogishvili, Zaza Avaliani, Nestani Tukvadze, Brent Little, Adam Bernheim, Timothy D. Read, Jeannette Guarner, Hartmut Derendorf, Charles A. Peloquin, Henry M. Blumberg, Sergo Vashakidze
Antimicrobial Agents and Chemotherapy May 2017, 61 (6) e00226-17; DOI: 10.1128/AAC.00226-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis
Russell R. Kempker, M. Tobias Heinrichs, Ketino Nikolaishvili, Irina Sabulua, Nino Bablishvili, Shota Gogishvili, Zaza Avaliani, Nestani Tukvadze, Brent Little, Adam Bernheim, Timothy D. Read, Jeannette Guarner, Hartmut Derendorf, Charles A. Peloquin, Henry M. Blumberg, Sergo Vashakidze
Antimicrobial Agents and Chemotherapy May 2017, 61 (6) e00226-17; DOI: 10.1128/AAC.00226-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antitubercular agents
pyrazinamide
Tuberculosis, Multidrug-Resistant
Tuberculosis, Pulmonary
tuberculosis
drug resistance
drug penetration
pyrazinamide
microdialysis
pharmacology

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596